Impact of autoimmune diseases on outcome of patients with early breast cancer.
Our aim was to analyze the impact of a concurrent autoimmune disease on outcome of patients with early breast cancer. We reviewed medical charts of patients with a diagnosis of autoimmune diseases (AD) among a population of 17.153 cases. We categorized ADs as endocrine, rheumatic, systemic, neurological diseases and vasculitis. For each patient in the study group, we matched 2 patients. The events to determine overall survival (OS) and disease free survival (DFS) were identified from follow-up data. We identified 279 (1.62%) patients with early breast cancer and concurrent ADs. The median follow-up was 7.0 years. The 10-year OS rate was 86% (95% CI, 80% to 91%) in the study group and 90% (95% CI, 86% to 93%) for the control group (p = 0.011). In patients with ER positive/HER2 negative subtype a worse OS was observed in the study group when compared to the control group (p = 0.0046); this difference remained statistically significant when the analysis was restricted to breast cancer mortality (p = 0.045). The 10-year DFS rate was 69% (95% CI, 61% to 76%) in the study group and 72% (95% CI, 66% to 77%) for the control group (p = 0.22). Autoimmunity at diagnosis of early breast cancer is associated with worse survival.
Division of Experimental Therapeutics, Istituto Europeo di Oncologia, Milano, Italy.
Carmen
C
Criscitiello
Division of Epidemiology and Biostatistics, Istituto Europeo di Oncologia, Milano, Italy.|Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milano, Italy.
Vincenzo
V
Bagnardi
Division of Experimental Therapeutics, Istituto Europeo di Oncologia, Milano, Italy.
Angela
A
Esposito
Division of Experimental Therapeutics, Istituto Europeo di Oncologia, Milano, Italy.
Lucia
L
Gelao
Division of Epidemiology and Biostatistics, Istituto Europeo di Oncologia, Milano, Italy.
Barbara
B
Santillo
Division of Experimental Therapeutics, Istituto Europeo di Oncologia, Milano, Italy.
Giulia
G
Viale
Division of Epidemiology and Biostatistics, Istituto Europeo di Oncologia, Milano, Italy.
Nicole
N
Rotmensz
Division of Experimental Therapeutics, Istituto Europeo di Oncologia, Milano, Italy.|Breast Cancer Program, Istituto Europeo di Oncologia, Milano, Italy.
Aron
A
Goldhirsch
Division of Experimental Therapeutics, Istituto Europeo di Oncologia, Milano, Italy.
Giuseppe
G
Curigliano
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001327:Autoimmune Diseases / Q000150:complications* / Q000175:diagnosis / Q000401:mortality; D001943:Breast Neoplasms / Q000150:complications* / Q000175:diagnosis* / Q000401:mortality; D016022:Case-Control Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D011379:Prognosis; D015996:Survival Rate
autoimmunity; clinical outcome; early breast cancer; endocrine therapy; immunology